Clinical trial
Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol…
NCT00449410 · Radboud University Medical Center, Other · Completed
Key facts
| NCT number | NCT00449410 |
|---|---|
| Title | Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients |
| Official title | Silent Cerebrovascular Lesion and Cognitive Decline Prevention in Atrial Fibrillation by Intensive Cholesterol Lowering in Elderly Patients |
| Acronym | SPACE |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | Pfizer Industry Schering-Plough |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation, Neuropsychology, Magnetic Resonance Imaging, Inflammation, Hemostasis |
| Intervention type | Drug |
| Interventions | Atorvastatin, ezetimibe |
| Enrollment | 35 |
| Start date | May 1, 2005 |
| Completion | Oct 1, 2006 |
| First posted | Mar 20, 2007 |
| Last update posted | Mar 20, 2007 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: